Chronic Evaluation of Novel Pacemaker System
- Conditions
- Ventricular Pacing With Rate ResponseBradycardia
- Registration Number
- NCT06056817
- Lead Sponsor
- Calyan Technologies
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not yet recruiting
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria:<br><br> 1. Age 18 or above<br><br> 2. Willing and capable of providing informed consent<br><br> 3. Class I or IIa indication for implantation of a single-chamber ventricular<br> pacemaker, according to ACC/AHA/HRS guidelines<br><br> 4. A life expectancy of at least one year, and is a suitable candidate based on overall<br> health and well-being<br><br>Exclusion Criteria:<br><br> 1. Patients with complete AV block or other pacemaker-dependent conditions<br><br> 2. Patients in whom a substernal device implant should be avoided:<br><br> 1. Any prior sternotomy;<br><br> 2. Any prior medical condition or procedure that leads to adhesions in the<br> anterior mediastinal space;<br><br> 3. Any marked sternal abnormality, such as pectus excavatum or pectus carinatum<br><br> 4. Prior abdominal surgery in the epigastric region<br><br> 5. Planned sternotomy<br><br> 6. Prior or planned chest radiotherapy<br><br> 7. Hiatal hernia that distorts mediastinal anatomy<br><br> 8. Adhesions in the anterior mediastinal space<br><br> 9. Severe obesity so that subxiphoid/substernal tunneling cannot be safely<br> performed<br><br> 3. Patients with severe RV dilation, gross hepatosplenomegaly, or severe obesity such<br> that subxiphoidal/substernal tunneling cannot be safely performed<br><br> 4. Patients with a class III indication for a permanent pacemaker<br><br> 5. Patients with decompensated heart failure not due to bradycardia and expected to<br> worsen with chronic RV pacing<br><br> 6. Patients with an implanted cardiac pacemaker, cardioverter defibrillator, cardiac<br> resynchronization device, or neurostimulator device, or planned implantation of a<br> cardioverter defibrillator, cardiac resynchronization device, or neurostimulator<br> device<br><br> 7. Patients with a current or planned implantation of a substernal device, or any<br> implanted device that would interfere with the implantation or operation of a<br> substernal device<br><br> 8. Patients who have previously undergone an open-heart surgical procedure.<br><br> 9. Patients with an active infection<br><br> 10. Patient on chronic oral anticoagulation which cannot be temporarily discontinued for<br> surgery<br><br> 11. Patients with a condition in which pericardial pacing would be difficult or<br> impossible, such as acute pericarditis, chronic pericardial effusion or pericardial<br> thickening or calcification, cardiac tamponade, or chronic restrictive pericarditis<br><br> 12. Patients who have tested positive for the COVID-19 in the past 3 months, or are<br> currently showing symptoms consistent with COVID-19<br><br> 13. Women of childbearing potential who are or might be pregnant at the time of the<br> study or breastfeeding<br><br> 14. Subjects with a life expectancy of less than 12 months<br><br> 15. Patients who are currently enrolled or planning to participate in any concurrent<br> clinical study with an investigational therapy<br><br> 16. Patients with decompensated heart failure expected to worsen with chronic RV pacing<br><br> 17. Patients with COPD with oxygen dependence
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence of procedure and device related serious adverse events (SAEs);Number of patients with successful chronic ventricular pacing
- Secondary Outcome Measures
Name Time Method